# DSC Investment

> DSC Investment is a VC fund backing Artificial Intelligence and Software. See 229 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 229
- Last investment: Jul 2026
- Lead investor: 15%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/dscinvestment/
- Website: http://dscinvestment.com

DSC Investment is a VC fund in Seoul focused on Artificial Intelligence and Software. DSC Investments invests in early stage and growth companies in the field of corporate identify and focus, IT, software, biotechnology, machinery, and future high-growth areas such as environment and resources.

## Contacts

5 contacts available for DSC Investment. Shizune tracks 6 team members at DSC Investment. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/dsc-investment?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $594k–$9.1M |
| Series A | $1.6M–$17M |
| Series B | $4.5M–$54M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Artificial Intelligence | 26 | 11% |
| Software | 21 | 9% |
| Health Care | 20 | 9% |
| Information Technology | 20 | 9% |
| Biotechnology | 18 | 8% |

191 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 77 | 34% |
| Series B | 51 | 22% |
| Seed | 41 | 18% |
| Series C | 16 | 7% |
| Funding Round | 6 | 3% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 128 | 56% |
| United States | 16 | 7% |
| Israel | 2 | 1% |
| Thailand | 1 | 0% |
| Russian Federation | 1 | 0% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Han Tae Hoon | Managing Director | 2 | https://shizune.co/investors/profile/han-tae-hoon |
| Junam Kim | Director | 4 | https://shizune.co/investors/profile/junam-kim |
| Kyungho Lee | Managing Director | 1 | https://shizune.co/investors/profile/kyungho-lee |
| Lee Yong-hyun | Head of the DSC Investment team | 3 | https://shizune.co/investors/profile/lee-yong-hyun |
| Yohan Kim | Senior Managing Director | 4 | https://shizune.co/investors/profile/yohan-kim-b6f2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MID | MID specializes in the development, testing, and production of space-related components. | $10.8M | Series A | Jul 29, 2026 |  |
| CarbonSix | CarbonSix develops AI-powered robotics technologies for manufacturing automation, with a focus on tasks that involve high product variation and changing production conditions. Its platform uses imitation learning to enable industrial robots to learn from human demonstrations and perform complex manipulation tasks that are difficult to automateusing conventional programming methods. The company combines robotics hardware and AI software to improve robot adaptability while meeting industrial quality and reliability requirements. Its solutions are designed for manufacturing environments where flexible automation is needed for assembly and other variable production processes. | $40M | Series A | Jul 01, 2026 |  |
| Inocras | Inocras Inc. specializes in whole genome sequencing and analytics, focusing on providing insights for personalized care in cancer and rare diseases. Utilizing artificial intelligence, Inocras aims to revolutionize healthcare by enabling precision medicine. The company offers services to patients, healthcare providers, researchers, and partners,seeking to unlock new possibilities in precision health. With a commitment to innovation, Inocras has introduced products like CancerVision and RareVision, designed to enhance diagnosis and treatment strategies through comprehensive genomic analysis. | $20K | Series B | Jul 01, 2026 |  |
| Clobe AI | Clobe AI is a SaaS-based financial management platform designed for businesses to monitor and manage cash flow and financial operations. The company provides services such as real-time aggregation of financial data from bank accounts, corporate cards, and tax invoices, along with automated accounting and tax handling. The platform also supportscash flow tracking, profit and loss analysis, and automated settlement workflows, including transaction mapping and invoice processing, enabling centralized financial reporting and operational control. | $9.1M | Seed | Mar 11, 2026 |  |
| Clobe ai | Clobe ai is an AI‑powered financial platform that simplifies money management for individuals and small‑to‑medium businesses. | $9.1M | Seed | Mar 11, 2026 |  |
| Ark | Ark is an AI-based early screening company focused on identifying and preventing complications associated with chronic diseases, developing and supplying advanced medical AI solutions that enable early detection, risk assessment, and proactive disease management to support healthcare providers in delivering more precise and timely care. | $13.5M | Series A | Mar 05, 2026 |  |
| Orum Therapeutics | Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification. | $98.3M | Post-IPO Equity | Dec 18, 2025 |  |
| arcreal | arcreal is involved in developing intraoral scanners, medical software, and dental platforms with the goal of digital transformation in the dental industry. They produce different technologies, such as an intraoral scanner, CAD software, and a digital platform. | $5.4M | Seed | Dec 16, 2025 |  |
| Pharos iBio Co. | Pharos iBio Co. specializing in drug development that develops treatments for intractable diseases. | $12.9M | Post-IPO Debt | Dec 04, 2025 |  |
| PineTree Therapeutics | PineTree Therapeutics engages in the development of disruptive therapies in Oncology and Immuno-oncology. | $47M | Series B | Oct 28, 2025 |  |

10 of 229 investments shown.

## Co-investors
- [Schmidt](https://shizune.co/investors/profile/schmidt-4d8d) — VC Fund, 57 deals together
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 28 deals together
- [Korea Development Bank](https://shizune.co/investors/profile/korean-development-bank) — VC Fund, 17 deals together
- [Mirae Asset Venture Investment](https://shizune.co/investors/profile/mirae-asset-venture-investment) — VC Fund, 17 deals together
- [Atinum Partners](https://shizune.co/investors/profile/atinum-partners) — VC Fund, 15 deals together
- [Capstone Partners](https://shizune.co/investors/profile/capstone-partners-korea) — VC Fund, 15 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [All Investors in South Korea](https://shizune.co/investors/investors-south-korea)
- [All VC Funds in South Korea](https://shizune.co/investors/vc-funds-south-korea)
- [SaaS Investors in South Korea](https://shizune.co/investors/saas-investors-south-korea)
- [SaaS VC Funds in South Korea](https://shizune.co/investors/saas-vc-funds-south-korea)
- [Software VC Funds in South Korea](https://shizune.co/investors/software-vc-funds-south-korea)
- [Enterprise Investors in South Korea](https://shizune.co/investors/enterprise-investors-south-korea)

## FAQ

### What does DSC Investment invest in?

DSC Investment invests primarily in Artificial Intelligence, Software and Health Care startups, most often at Series A and Series B stage. Most of the 229 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is DSC Investment's check size?

DSC Investment typically joins rounds of $594k–$9.1M at Seed, $1.6M–$17M at Series A and $4.5M–$54M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds DSC Investment participates in.

### How do I contact DSC Investment?

Public channels for DSC Investment include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at DSC Investment?

The team at DSC Investment includes Han Tae Hoon (Managing Director), Junam Kim (Director) and Kyungho Lee (Managing Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co